Literature DB >> 3857965

Oncogene mobility in a human leukemia line HL-60.

S R Wolman, L Lanfrancone, R Dalla-Favera, S Ripley, A S Henderson.   

Abstract

HL-60, a cell line derived from a human promyelocytic leukemia, shows amplification of the oncogene c-myc. Chromosome aberrations reported in HL-60 include double minutes (DMs) and an abnormally banded region (ABR) on chromosome #8. A relationship between these chromosomal aberrations and amplification of c-myc DNA has been suggested. We report the localization by cytologic hybridization of amplified c-myc DNA to a marker chromosome, M3q+, in an early passage of HL-60. The localization of c-myc to an ABR on an 8q+ chromosome was confirmed in later passage clones. The most probable derivation of the M3q+ chromosome is t(5p;17q) with additional material associated with c-myc amplification inserted into 17q. This localization is of interest in light of the association between t(15:17) and promyelocytic leukemia. The results indicate that amplification and chromosome integration can occur at a site other than the native gene locus and at different integration sites in different lineages of the same tumor.

Entities:  

Mesh:

Year:  1985        PMID: 3857965     DOI: 10.1016/0165-4608(85)90023-8

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  3 in total

Review 1.  The HL60 cell line: a model system for studying human myeloid cell differentiation.

Authors:  G D Birnie
Journal:  Br J Cancer Suppl       Date:  1988-12

2.  Double minutes arise from circular extrachromosomal DNA intermediates which integrate into chromosomal sites in human HL-60 leukemia cells.

Authors:  D D Von Hoff; B Forseth; C N Clare; K L Hansen; D VanDevanter
Journal:  J Clin Invest       Date:  1990-06       Impact factor: 14.808

3.  Isolation and characterization of a spontaneously arising long-lived line of human keratinocytes (NM 1).

Authors:  H P Baden; J Kubilus; J C Kvedar; M L Steinberg; S R Wolman
Journal:  In Vitro Cell Dev Biol       Date:  1987-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.